Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outper

CRISPR Therapeutics (NASDAQ:CRSP) today presented durability data from its Phase 1a clinical trial e

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outper

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation,

Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on posi

Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

Bank of America Corp DE lowered its position in shares of CRISPR Therapeutics AG (NASDAQ: CRSP) by 1

Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"

CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipe

CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and ra

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Con

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the anal

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) to

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.44, moving +1.68% from the p

CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on t

Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely e

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $46.54, indicating a -2.

Ark Investment Management's high-profile stock picker Cathie Wood has bought stakes in CRISPR Therap

Amova Asset Management Americas Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ: CRSP) by

CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved as

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid a

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $47.78, marking a -1.63% move

CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) w

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outper

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Cathie Wood’s ARK Innovation ETF is shedding assets this year as it continues to underperform the te

Bernstein analyst William Pickering maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Market Per

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and ra

Piper Sandler analyst Edward Tenthoff reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Overwei

CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshad

- CRISPR Therapeutics AG (NASDAQ:CRSP) (the "Company") today announced its intention to offe

US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving l

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy an

CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pip

TD Cowen analyst Tyler Van Buren maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Hold and rais

Evercore ISI Group analyst Liisa Bayko maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperf

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes

Cathie Wood's Ark Invest unveiled its "big ideas" for 2025 in a cryptic list, challengin

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s